Humacyte, Inc. (HUMA)
NASDAQ: HUMA · Real-Time Price · USD
0.5425
+0.0425 (8.50%)
At close: Nov 19, 2026, 4:00 PM EST
0.5409
-0.0016 (-0.29%)
After-hours: Nov 19, 2026, 7:58 PM EST
Humacyte Revenue
Humacyte had revenue of $1.03M in the quarter ending September 30, 2026, with 36.52% growth. This brings the company's total for the last twelve months to $2.40M, up 52.51% year-over-year. In the year 2025, Humacyte had annual revenue of $2.04M. That makes Humacyte the 42,018th largest company in the world by revenue and 5,687th in the United States.
Revenue (ttm)
$2.40M
Revenue Growth
+52.51%
P/S Ratio
62.90
Revenue / Employee
$13,022
Employees
184
Market Cap
150.71M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.04M | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 1.57M | 302.00K | 23.91% |
| Dec 31, 2021 | 1.26M | -228.00K | -15.29% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| MacroGenics | 140.81M |
| Sutro Biopharma | 45.11M |
| Atrium Therapeutics | 38.82M |
| Zentalis Pharmaceuticals | 26.87M |
| Veraxa Biotech AG | 29.54K |
HUMA News
- 14 hours ago - Humacyte submits ATEV sBLA to FDA - TheFly
- 14 hours ago - Humacyte Submits Supplemental Biologics License Application to FDA for the Acellular Tissue Engineered Vessel in Dialysis Access - GlobeNewsWire
- 3 days ago - Humacyte findings show low atherosclerosis susceptibility in ATEV - TheFly
- 3 days ago - Humacyte Presents Long-Term Clinical Data Demonstrating Low Atherosclerosis Susceptibility in Acellular Tissue Engineered Vessel - GlobeNewsWire
- 8 days ago - Five Presentations, One Leading Innovation: Humacyte's Acellular Tissue Engineered Vessel Takes Center Stage at VEITH 2026 - GlobeNewsWire
- 8 days ago - Humacyte price target raised to 60c from 50c at Barclays - TheFly
- 9 days ago - Humacyte reports Q3 EPS (6c), consensus (8c) - TheFly
- 9 days ago - Humacyte Earnings Call Transcript: Q3 2026 - Transcripts